Arrowhead Pharmaceuticals Company Profile (NASDAQ:ARWR)

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ARWR
  • CUSIP: N/A
  • Web: www.arrowheadpharma.com
Capitalization:
  • Market Cap: $119.64 million
  • Outstanding Shares: 74,772,000
Average Prices:
  • 50 Day Moving Avg: $1.62
  • 200 Day Moving Avg: $2.10
  • 52 Week Range: $1.20 - $8.22
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.76
  • P/E Growth: -0.44
Sales & Book Value:
  • Annual Revenue: $13.42 million
  • Price / Sales: 8.91
  • Book Value: $1.26 per share
  • Price / Book: 1.27
Profitability:
  • EBIDTA: ($61,940,000.00)
  • Net Margins: -1,663.58%
  • Return on Equity: -89.07%
  • Return on Assets: -64.08%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 2.87%
  • Quick Ratio: 2.87%
Misc:
  • Average Volume: 726,606 shs.
  • Beta: 2.08
  • Short Ratio: 13.41
 

Frequently Asked Questions for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.04. The firm had revenue of $8.99 million for the quarter, compared to analyst estimates of $4.19 million. Arrowhead Pharmaceuticals had a negative return on equity of 89.07% and a negative net margin of 1,663.58%. View Arrowhead Pharmaceuticals' Earnings History.

Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2017?

5 brokers have issued twelve-month price objectives for Arrowhead Pharmaceuticals' shares. Their forecasts range from $1.00 to $2.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $1.80 in the next twelve months. View Analyst Ratings for Arrowhead Pharmaceuticals.

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 11,413,501 shares, a decrease of 12.3% from the April 28th total of 13,008,193 shares. Based on an average daily trading volume, of 1,004,315 shares, the short-interest ratio is presently 11.4 days. Approximately 17.8% of the company's shares are short sold.

Who are some of Arrowhead Pharmaceuticals' key competitors?

Who owns Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.00%), OppenheimerFunds Inc. (0.00%), Prescott Group Capital Management L.L.C. (2.56%), Perceptive Advisors LLC (1.13%), Geode Capital Management LLC (0.00%) and Bank of New York Mellon Corp (0.42%). Company insiders that own Arrowhead Pharmaceuticals stock include Douglas B Given, Kenneth Allen Myszkowski and Mauro Ferrari. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Who sold Arrowhead Pharmaceuticals stock? Who is selling Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Tudor Investment Corp ET AL, Goldman Sachs Group Inc., Credit Suisse AG, TIAA CREF Investment Management LLC, California Public Employees Retirement System and Alliancebernstein L.P.. Company insiders that have sold Arrowhead Pharmaceuticals stock in the last year include Douglas B Given and Kenneth Allen Myszkowski. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Who bought Arrowhead Pharmaceuticals stock? Who is buying Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, SG Americas Securities LLC, UBS Asset Management Americas Inc., Teachers Advisors LLC, Geode Capital Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy Arrowhead Pharmaceuticals stock?

Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Arrowhead Pharmaceuticals stock cost?

One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $1.60.

Analyst Ratings

Consensus Ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) (?)
Ratings Breakdown: 5 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.80 (12.50% upside)

Analysts' Ratings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/12/2017Jefferies Group LLCReiterated RatingHold$2.00LowView Rating Details
11/30/2016William BlairDowngradeOutperform -> Market Perform$12.00 -> $2.00N/AView Rating Details
11/30/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$10.00 -> $2.00N/AView Rating Details
11/30/2016Cantor FitzgeraldDowngradeBuy -> Hold$15.00 -> $1.00N/AView Rating Details
11/30/2016Chardan CapitalDowngradeBuy -> Neutral$8.00 -> $2.00N/AView Rating Details
8/5/2015Royal Bank of CanadaReiterated RatingHold$9.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Earnings History by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q2 2017($0.12)($0.08)$4.19 million$8.99 millionViewListenView Earnings Details
2/6/2017Q117($0.20)($0.17)$13.24 million$4.37 millionViewListenView Earnings Details
8/9/2016Q316($0.37)($0.32)$0.05 million$39.58 millionViewN/AView Earnings Details
5/10/2016Q216($0.37)($0.35)$0.26 million$0.04 millionViewListenView Earnings Details
2/9/2016Q1($0.41)($0.32)$0.29 million$0.04 millionViewN/AView Earnings Details
12/14/2015Q415($0.39)($0.42)$0.14 million$0.04 millionViewListenView Earnings Details
8/4/2015Q315($0.38)($0.27)$0.11 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q214($0.35)($0.33)$110.00 million$43.75 millionViewListenView Earnings Details
2/9/2015Q114($0.32)($0.41)$0.24 million$0.17 millionViewN/AView Earnings Details
11/25/2014Q413($0.25)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
8/12/2014Q313($0.22)($0.22)$0.04 million$0.04 millionViewN/AView Earnings Details
5/6/2014Q2 2014($0.18)($0.31)$0.05 million$0.04 millionViewN/AView Earnings Details
2/4/2014Q4($0.18)($0.33)ViewN/AView Earnings Details
12/18/2013Q4($0.23)($0.43)ViewListenView Earnings Details
5/9/2013Q2 2013($0.41)ViewN/AView Earnings Details
2/13/2013Q1 2013($0.33)ViewN/AView Earnings Details
12/20/2012Q4 2012($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
2017 EPS Consensus Estimate: ($0.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.22$0.22$0.22
Q2 20172($0.16)($0.11)($0.14)
Q3 20172($0.15)($0.13)($0.14)
Q4 20172($0.16)($0.10)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Insider Ownership Percentage: 4.57%
Institutional Ownership Percentage: 41.41%
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Douglas B. GivenDirectorSell12,000$6.72$80,640.00View SEC Filing  
8/23/2016Kenneth Allen MyszkowskiCFOSell6,900$8.00$55,200.00View SEC Filing  
8/22/2016Kenneth Allen MyszkowskiCFOSell13,100$8.00$104,800.00View SEC Filing  
12/30/2015Kenneth Allen MyszkowskiCFOSell23,347$6.13$143,117.11View SEC Filing  
10/28/2015Mauro FerrariDirectorBuy400$7.62$3,048.00View SEC Filing  
10/9/2015Mauro FerrariDirectorBuy1,900$6.19$11,761.00View SEC Filing  
1/5/2015David L LewisInsiderSell15,000$8.01$120,150.00View SEC Filing  
10/15/2014Christopher Richard AnzaloneCEOBuy16,000$6.32$101,120.00View SEC Filing  
10/1/2014Charles MckenneyDirectorSell2,500$14.70$36,750.00View SEC Filing  
9/30/2014David L LewisInsiderSell15,000$15.02$225,300.00View SEC Filing  
9/26/2014Douglas B GivenDirectorSell2,000$15.24$30,480.00View SEC Filing  
6/9/2014Charles MckenneyDirectorSell22,000$14.32$315,040.00View SEC Filing  
2/12/2014Kenneth Allen MyszkowskiCFOSell16,000$18.77$300,320.00View SEC Filing  
2/7/2014Edward W FrykmanDirectorSell3,148$15.98$50,305.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Latest Headlines for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 16, 2017
finance.yahoo.com - May 16 at 3:44 PM
americanbankingnews.com logoResearch Analysts Set Expectations for Arrowhead Pharmaceuticals Inc's FY2017 Earnings (ARWR)
www.americanbankingnews.com - May 15 at 8:52 AM
americanbankingnews.com logoArrowhead Pharmaceuticals Inc (ARWR) Short Interest Up 13.3% in April
www.americanbankingnews.com - May 11 at 7:00 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Arrowhead Pharmaceuticals Inc (ARWR) Reduced by Analyst
www.americanbankingnews.com - May 8 at 9:10 AM
finance.yahoo.com logoETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 5, 2017
finance.yahoo.com - May 5 at 8:42 PM
americanbankingnews.com logoArrowhead Pharmaceuticals Inc (ARWR) Expected to Announce Quarterly Sales of $4.19 Million
www.americanbankingnews.com - May 5 at 3:52 PM
finance.yahoo.com logoArrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 5 at 3:41 PM
americanbankingnews.com logoArrowhead Pharmaceuticals Inc (ARWR) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - May 4 at 9:00 PM
finance.yahoo.com logoEdited Transcript of ARWR earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 3:43 PM
seekingalpha.com logoArrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 3 at 8:44 PM
finance.yahoo.com logoArrowhead Reports Fiscal 2017 Second Quarter Results
finance.yahoo.com - May 3 at 8:44 PM
americanbankingnews.com logoArrowhead Pharmaceuticals Inc (ARWR) Expected to Announce Earnings of -$0.12 Per Share
www.americanbankingnews.com - May 3 at 8:12 AM
americanbankingnews.com logoFavorable News Coverage Very Likely to Impact Arrowhead Pharmaceuticals (ARWR) Stock Price
www.americanbankingnews.com - May 2 at 7:30 PM
americanbankingnews.com logoArrowhead Pharmaceuticals Inc (ARWR) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 1 at 12:22 PM
americanbankingnews.com logoPositive Media Coverage Extremely Likely to Affect Arrowhead Pharmaceuticals (ARWR) Share Price
www.americanbankingnews.com - April 28 at 9:48 AM
finance.yahoo.com logoArrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results
finance.yahoo.com - April 26 at 9:03 PM
streetinsider.com logoArrowhead Research (ARWR) Presents ARC-AAT Clinical Data at ILC
www.streetinsider.com - April 26 at 3:54 PM
streetinsider.com logoArrowhead Research (ARWR) Presents ARC-AAT Clinical Data at ILC - StreetInsider.com
www.streetinsider.com - April 24 at 3:42 PM
finance.yahoo.com logoArrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™
finance.yahoo.com - April 24 at 10:34 AM
americanbankingnews.com logoArrowhead Pharmaceuticals (ARWR) Earning Favorable News Coverage, Study Shows
www.americanbankingnews.com - April 22 at 1:14 PM
finance.yahoo.com logoArrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™
finance.yahoo.com - April 20 at 3:43 PM
finance.yahoo.com logoETFs with exposure to Arrowhead Pharmaceuticals, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 3:41 PM
americanbankingnews.com logoArrowhead Pharmaceuticals (ARWR) Earns Daily Coverage Optimism Score of 0.22
www.americanbankingnews.com - April 18 at 8:52 AM
americanbankingnews.com logo$4.19 Million in Sales Expected for Arrowhead Pharmaceuticals Inc (ARWR) This Quarter
www.americanbankingnews.com - April 14 at 3:20 PM
americanbankingnews.com logoArrowhead Pharmaceuticals (ARWR) Receiving Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 13 at 5:52 PM
americanbankingnews.com logoArrowhead Pharmaceuticals Inc (ARWR) Receives Hold Rating from Jefferies Group LLC
www.americanbankingnews.com - April 12 at 3:15 PM
americanbankingnews.com logoArrowhead Pharmaceuticals Inc (ARWR) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 12 at 1:00 PM
americanbankingnews.com logo Analysts Expect Arrowhead Pharmaceuticals Inc (ARWR) to Announce -$0.12 EPS
www.americanbankingnews.com - April 12 at 8:15 AM
finance.yahoo.com logoArrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™
finance.yahoo.com - April 7 at 8:07 AM
finance.yahoo.com logoArrowhead Pharmaceuticals Adopts Stockholder Rights Agreement
finance.yahoo.com - March 23 at 4:04 PM
finance.yahoo.com logo7:31 am Arrowhead adopts poison pill in accordance with an authorization and declaration from its board of directors of a dividend distribution of one preferred share purchase right on each outstanding share of the company's common stock
finance.yahoo.com - March 23 at 4:04 PM
biz.yahoo.com logoARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification
biz.yahoo.com - March 23 at 4:04 PM
finance.yahoo.com logoARROWHEAD PHARMACEUTICALS, INC. Financials
finance.yahoo.com - February 10 at 4:07 PM
biz.yahoo.com logoARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
us.rd.yahoo.com - February 8 at 8:52 PM
finance.yahoo.com logoEdited Transcript of ARWR earnings conference call or presentation 6-Feb-17 9:30pm GMT
finance.yahoo.com - February 7 at 4:32 PM
us.rd.yahoo.com logoArrowhead Reports Fiscal 2017 First Quarter Results
us.rd.yahoo.com - February 6 at 8:40 PM
biz.yahoo.com logoQ1 2017 Arrowhead Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - February 6 at 3:39 PM
finance.yahoo.com logoDrug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on Arrowhead Pharmaceuticals and Jaguar Animal Health
finance.yahoo.com - February 1 at 3:47 PM
finance.yahoo.com logoArrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results
finance.yahoo.com - January 30 at 4:41 PM
finance.yahoo.com logoRobbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - January 20 at 9:44 PM
finance.yahoo.com logoIMPORTANT ARWR SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - January 14 at 8:39 PM
globenewswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class ... - GlobeNewswire (press release)
globenewswire.com - January 14 at 4:23 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Arrowhead Pharmaceuticals, Inc. and Certain Officers – ARWR
finance.yahoo.com - January 13 at 9:11 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – ARWR
finance.yahoo.com - January 13 at 4:09 PM
thestreet.com logoThese 3 Biotech Stocks Are Already Moving Wildly on Thursday
us.rd.yahoo.com - January 12 at 8:40 PM

Social

Chart

Arrowhead Pharmaceuticals (ARWR) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff